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Abstract: White adipose tissue (WAT) is a highly adaptive endocrine organ that continuously 
remodels in response to nutritional cues. WAT expands to store excess energy by increasing 
adipocyte number and/or size. Failure in WAT expansion has serious consequences on metabolic 
health resulting in altered lipid, glucose, and inflammatory profiles. Besides an impaired 
adipogenesis, fibrosis and low-grade inflammation also characterize dysfunctional WAT. 
Nevertheless, the precise mechanisms leading to impaired WAT expansibility are yet unresolved. 
Autophagy is a conserved and essential process for cellular homeostasis, which constitutively 
allows the recycling of damaged or long-lived proteins and organelles, but is also highly induced 
under stress conditions to provide nutrients and remove pathogens. By modulating protein and 
organelle content, autophagy is also essential for cell remodeling, maintenance, and survival. In this 
line, autophagy has been involved in many processes affected during WAT maladaptation, 
including adipogenesis, adipocyte, and macrophage function, inflammatory response, and fibrosis. 
WAT autophagy dysregulation is related to obesity and diabetes. However, it remains unclear 
whether WAT autophagy alteration in obese and diabetic patients are the cause or the consequence 
of WAT malfunction. In this review, current data regarding these issues are discussed, focusing on 
evidence from human studies.  
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1. Introduction 
Obesity is considered a major health problem which prevalence has globally increased over the 
last decades [1,2]. Obesity, which is defined by an increased white adipose tissue (WAT) mass, entails 
an increased risk of several chronic illnesses including type 2 diabetes (T2D) and insulin resistance, 
cardiovascular diseases (CVD), hepatic steatosis and even several types of cancer [1–3]. Adipose 
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tissue (AT) dysfunction, beyond AT mass, has been proposed as a key player in the development of 
obesity-related complications [4,5].  
AT function is essential for the correct metabolic regulation [6,7]. There are distinct AT depots 
with divergent functions. WAT mainly stores excess energy as triglycerides after feeding and 
mobilizes lipids during fasting to meet the energy demands from other tissues. By contrast, brown 
(BAT) and beige or brite (brown-into-white) AT are thermogenic tissues that burn energy. Notably, 
WAT, BAT, and beige AT exert relevant functions as endocrine organs by releasing adipokines (or 
batokines in the case of BAT) such as hormones, cytokines, or microRNAs, which regulate and 
participate in the crosstalk with other metabolic organs (e.g., liver, muscle, brain). This allows the 
integration of metabolic signals to comply with body energy requirements depending on 
environmental cues [8–10]. In addition, different roles in energy homeostasis have been attributed to 
WAT depots depending on their location, i.e., visceral (vWAT) or subcutaneous (sWAT) [4]. 
Therefore, the maintenance of proper AT function is crucial in keeping metabolic health.  
Among the molecular and cellular processes involved in AT functioning, autophagy has 
emerged as a crucial cellular phenomenon for AT homeostasis [11,12]. Autophagy is a highly 
conserved homeostatic process essential for the survival of eukaryotic cells [13,14]. Damaged, 
redundant, or long-lived intracellular components are degraded into lysosomes through autophagy. 
Moreover, intracellular pathogens (and more recently demonstrated, extracellular microbial) and 
their components can be also eliminated by autophagy [15–17]. Besides allowing the turnover of 
organelles and intracellular molecules, autophagy is a source of macromolecules and nutrients 
during starvation. Autophagy is highly responsive to the nutritional status and is tightly regulated 
by the same mechanisms involved in the maintenance of metabolic homeostasis and the response to 
the feeding state e.g., insulin. Reciprocally, autophagy regulates many processes related to 
metabolism e.g., food intake by hypothalamic neurons, the differentiation and the fate of adipocytes 
or maintenance of β-cells, and hepatocytes structure and function for proper metabolic regulation 
[11,18–20]. However, there are many gaps regarding the precise relationship between autophagy and 
metabolic homeostasis. In the context of obesity and obesity-related diseases, the role of autophagy 
imbalance in AT remains unclear and somewhat contradictory, but their pivotal role in adipocyte fate 
and its close relationship with metabolism, highlight autophagy as an appealing target for targeting 
WAT dysfunction. 
In this review, we summarize the latest findings regarding the role of autophagy in the 
physiology of WAT (the main contributor for the obese phenotype and related-metabolic 
disturbances) and the impact of WAT autophagy dysregulation on systemic metabolic homeostasis. 
We will particularly focus on how autophagy is involved in WAT expansion, which not only depends 
on the formation of new adipocytes and adipocyte growth but also on essential processes which 
define the limits of WAT expandability such as inflammation and fibrosis. Eventually, a 
comprehensive description and discussion of the current literature on human WAT autophagy 
regarding obesity and glycemic status is presented, including intervention studies for weight loss 
and metabolic improvement. We also highlight the current limitations and unsolved questions that 
need to be addressed in subsequent studies analyzing autophagy in WAT. 
2. The Role of WAT Dysfunction in Metabolic Homeostasis 
WAT is a key player in metabolic homeostasis not only as an energy reservoir but also as an 
endocrine organ [7]. Adipocytes store excess energy in the form of triglycerides inside intracellular 
lipid droplets during feeding, and releases free fatty acids into the circulation to meet body energy 
requirements during fasting [9]. These processes have to be tightly regulated as the lack of excess 
energy storage and/or enhanced fatty acid release can have serious consequences for the health of the 
individual. In addition, WAT participates in metabolic endocrine regulation by secreting endocrine 
mediators which not only play a relevant role in integrating metabolic signals [8,9,21], but also in 
other biological processes such as reproduction or immune response [22,23]. Furthermore, adipocytes 
with thermogenic capacity in WAT, i.e., beige adipocytes, which emerge in response to 
environmental cold and other stimuli (browning), also participate in the maintenance of WAT and 
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body homeostasis [9,10,24]. Interestingly, brown and beige adipocytes can also transdifferentiate into 
white adipocytes (whitening) [25,26]. 
To house the energy surplus, adult WAT expansion occurs by hypertrophy (adipocyte size 
increase due to triglyceride accumulation, i.e., lipogenesis) and/or by hyperplasia (increase in cell 
number by the proliferation of adipocyte precursors, preadipocytes, and their differentiation into 
new adipocytes, i.e., adipogenesis). The formation of new vasculature (angiogenesis) for correct 
oxygen and nutrient supply occurs concomitantly [27]. Together with these phenomena, extracellular 
matrix (ECM) remodels to accommodate these cellular changes [4,9,28]. 
The increased WAT size in obesity has been considered a major contributor for the development 
of obesity comorbidities [27,29]. However, there are also obese subjects who are apparently 
metabolically healthy without alterations related to metabolic syndrome (high glucose and 
triglyceride levels, high blood pressure, low HDL-cholesterol levels, insulin resistance) [30–33]. On 
the other hand, some non-obese individuals display an unfavorable metabolic profile and are at high 
risk of CVD [34,35]. What is more, patients with lipodystrophy (i.e., abnormal WAT distribution 
characterized by total or partial loss of this tissue) have the same metabolic alterations as obese 
subjects [36,37]. Given these paradoxical phenotypes regarding adiposity and metabolic 
dysregulation, it has been proposed that it is not the total body fat mass but the capacity of WAT to 
healthily expand which determines the metabolic status of the individual [5,38]. However, the precise 
mechanisms underlying the pathogenic processes which determine the threshold for the 
transformation of WAT into a dysfunctional organ, are not fully understood. 
It has been suggested that continuous energy flow to WAT can result in tissue stress and failure. 
Distressed hypertrophic adipocytes display an impaired lipogenic capacity and an altered 
proinflammatory secretory profile. This proinflammatory state further impairs WAT function by 
interfering with local insulin signaling (which governs transcriptional regulation of nutrient up-take 
and lipid storage by adipocytes and adipocyte formation), recruiting pro-inflammatory immune cells 
and promoting tissue fibrosis (ECM maladaptive remodeling). WAT fibrosis develops due to an 
altered synthesis and degradation of the ECM by tissue-resident cells, and promotes further 
adipocyte dysfunction by mechanical stress (due to increased contact with neighboring cells and the 
ECM), limiting cell size increase [39–41]. Therefore, a harmful vicious circle is initiated in 
dysfunctional WAT. This pathological response of WAT is usually related to hypertrophic adipocytes 
rather than hyperplasic ones. Large hypertrophic adipocytes are associated with an impaired glucose 
metabolism and metabolic alterations while small adipocytes are often correlated with decreased 
susceptibility to developing diabetes [4,7]. As they increase in size, adipocytes experience mechanical 
and hypoxic stress. At the intracellular level, hypertrophic adipocytes exhibit endoplasmic reticulum 
(ER) stress, mitochondrial dysfunction, and oxidative stress, which come together with the activation 
of inflammatory pathways [9,42]. By contrast, hyperplasic adipocytes and adipogenesis are 
associated with reduced hypoxic stress and inflammation, providing a lipid sink that can alleviate, at 
least in part, the inability of hypertrophied, dysfunctional adipocytes to store lipids [43].  
Inefficient lipid sequestration by adipocytes causes high plasma lipid levels (hyperlipidemia) 
and toxic lipid accumulation (lipotoxicity) in non-fatty organs such as the liver, muscle, or heart, 
which has been linked to the development of systemic insulin resistance [9,21,44]. Additionally, 
secreted proinflammatory factors from WAT into the circulation, also compromise insulin signaling 
and functioning of other organs [21,28,45]. Notably, the type of WAT depot, visceral (vWAT) or 
subcutaneous (sWAT), also have differential roles in energy dysregulation during metabolic 
disturbance [4]. vWAT accumulation (central obesity) is typically associated with metabolic 
complications, while increased sWAT (peripheral obesity) has been related to a more favorable 
metabolic profile. The opposite relationship of increased vWAT and sWAT with metabolic health 
may be due to the intrinsic characteristics and differential functions of each WAT depot [9,21]. 
Although food intake overload was initially proposed as the triggering factor for WAT 
dysfunction, it is not fully clear what comes first: adipocyte dysfunction, inflammation, or fibrosis. 
Therefore, the study of cellular and molecular mechanisms involved in these processes is of equal 
relevance in order to understand WAT pathophysiology and its consequences in body metabolic 
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health. Within this context, autophagy has been positioned at the crossroad of several essential 
cellular processes for WAT homeostasis. Roles reported for autophagy in the different processes 
involved in WAT expansion are discussed in the following sections.  
3. Autophagy 
Autophagy is a catabolic process that eliminates redundant or damaged intracellular 
components by delivering them to lysosomes. This degradative process is essential for maintaining 
cell homeostasis (constitutive autophagy), but can be also highly induced (adaptive autophagy) 
during starvation (to provide nutrients for energy supply and macromolecules), stress conditions 
(e.g., oxidative o ER stress, which result in an increase of damaged molecules), or infection (for 
intracellular or extracellular (secretory autophagy) pathogen degradation [13,17,46–48]. 
Consequently, autophagy is essential for the correct functioning of every organ in the body. 
Concordant to the role of autophagy as an adaptive response to nutrient deprivation, this process is 
mainly regulated by mediators involved in nutrient sensing (e.g., insulin, mTOR, glycogen) and is 
intimately related to metabolic homeostasis [13,46,49–53]. Furthermore, autophagy up-regulation is 
associated with inflammatory response and cellular stress related to adipocyte dysfunction [54,55]. 
Autophagy activation has been mainly related to cell survival. In fact, upregulated basal 
autophagy can promote longevity and prevent premature aging [56]. However, an enhanced 
autophagic flux may also lead to cellular death due to excess cytoplasm degradation [57]. Notably, 
autophagy deficiency also has detrimental effects on cell functioning by the accumulation of 
dysfunctional proteins and organelles and/or diminished defenses against pathogens, which can also 
lead to cell death [55,58]. The relevance of tight regulation of autophagy is highlighted by the 
association between autophagic imbalance and several disorders including diabetes, obesity, cancer, 
or neurodegeneration [54,59,60]. Within this context, dysregulated autophagy can be related to the 
development of the WAT and systemic low-grade inflammatory state present in metabolic diseases 
[61].   
Mammalian autophagy has been extensively reviewed elsewhere [13,62,63]. Briefly, according 
to the delivery route to lysosomes, there are three types of autophagy: (1) macroautophagy, which 
implies the sequestering of part of the cytoplasm and intracellular components into a double-
membrane vesicle, so-called autophagosome, which fuses with the lysosome; (2) microautophagy by 
which lysosomal membrane invaginations directly engulf cytoplasmic material; and (3) chaperone-
mediated autophagy (CMA) which does not require the sequestration of cargo (targets for 
degradation) by biological membranes. In CMA, cargo is selectively delivered via chaperones to 
lysosomes. The cargo-chaperone complex is recognized and translocated into lysosomes through a 
lysosomal membrane translocation complex composed of lysosome-associated membrane protein 
type (LAMP)-2 [47]. It was initially thought that, in contrast to CMA, macro- and microautophagy 
were non-selective ways of autophagy, mainly responsible for adaptive bulk autophagy in response 
to nutrient deprivation and other stressful conditions. To date, it is well established that these two 
vesicle-mediated ways of autophagy can also selectively degrade molecules and organelles [47,48,64–
66].  
3.1. Macroautophagy Pathway 
Macroautophagy (hereafter referred to as autophagy) is the most studied type of autophagy. 
Although non-selective bulk autophagy was mainly described to be up-regulated as an adaptive 
response, it also occurs at low basal levels to facilitate the turn-over of cell components and recycling. 
Additionally, selective autophagy removes specific dysfunctional and/or redundant organelles and 
molecules as well as intracellular pathogens by means of receptor-mediated cargo recognition [48,64]. 
Selective autophagy also provides specific nutrients depending on environmental cues, allowing the 
adaptation to lipid imbalance or amino acid, iron, or glucose shortage [13,48]. Autophagic processes 
are also classified according to the cargo to be degraded, e.g., mitochondria (mitophagy), aggregated 
proteins (aggrephagy), peroxisomes (pexophagy), lipid droplets (lipophagy), intracellular pathogens 
(xenophagy), and ER (reticulophagy) among others [48]. Interestingly, selective autophagy plays a 
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key role in cellular remodeling which becomes especially relevant in WAT adaptation to nutritional 
status [11,48], as discussed later.  
The autophagy process is orchestrated by core machinery consisting of several “autophagy-
related genes” (ATG) [67]. The participation of the different ATGs occur in consecutive phases that 
can be summarized as: (1) initiation or induction, (2) nucleation, (3) elongation and autophagosome 
formation, (4) autophagosome maturation and (5) autophagosome-lysosome fusion and cargo 
degradation.  
Autophagy induction leads to the recruitment of ATGs to the phagophore assembly site (PAS) 
and nucleation of the phagophore (a cup-shaped doubled-membrane which is the initial piece of the 
autophagosome). This process is initiated by de-phosphorylation, dissociation from mTORC1, and 
consequent activation of the serine/threonine kinase ULK1/2 which forms part of the ULK1/2 complex 
together with ATG13, ATG101, and FIP200. ULK1/2 complex triggers phagophore nucleation by 
phosphorylating and activating several components of the PI3KC3 complex (VPS34 - Beclin1 - 
Ambra1 - ATG14 - p115) [46,49,50]. PI3KC3 complex enhances local PI3P production at PAS and 
recruits the effector proteins WIPIs and DFCP1 to the omegasome (ER-emanating membrane domain) 
which initiates double-membrane vesicle nucleation [68–70]. ATG12-ATG5-ATG16L complex 
(previously conjugated by the action of ATG7 and ATG10) is recruited by WIPI by binding ATGL16.  
A second conjugation system that involves ATG8-family proteins (e.g., LC3 and GABARAPs) is 
required for phagophore elongation. LC3 precursor is processed by ATG4, generating the soluble 
LC3 form (LC3-I). LC3-I is conjugated to membrane phosphatidylethanolamine (PE) by the action of 
ATG7, ATG3, and the ATG12-ATG5-ATG16L complex. This gives rise to the membrane-associated 
lipidated LC3 form (LC3-II) [71]. Lipidated ATG8 family members attract components that contain 
the LC3-interacting region (LIR) for phagophore elongation but also serve as cargo recruiting agents 
in selective autophagy by interacting with LIR of cargo receptors e.g., p62 or sequestosome. These 
cargo receptors recognize the cargo through degradation signals such as ubiquitin.  
Gradual elongation of the phagophore curved membrane results in a sphere which rounds part 
of the cytoplasm, including autophagic cargo and eventually seals, giving rise to the doubled-
membrane autophagosome which encapsulates and isolates cytosolic material together with the 
cargo. Though PAS is thought to be mainly located at ER-emanating membrane domains (named 
omegasomes), other organelles such as the plasma membrane or the Golgi complex have been 
recently proposed as PASs [72]. It is thought that a mechanism mediated by ATG9-containing vesicles 
contributes to phagophore expansion through the addition of these cellular membranes [73].  
Once autophagosomal membranes seal, autophagosome maturation takes place involving ATGs 
clearance from the outer membrane and the recruitment of machinery for lysosomal delivery and 
fusion [74,75]. After dissociation of autophagy protein machinery, the exterior membrane of the 
autophagosome fuses with the lysosomal membrane, resulting in the release of a single-membrane 
autophagic body into the autolysosome that, together with the autophagic cargo, will be degraded 
by lysosomal hydrolytic enzymes and the resulting usable nutrients are released back to the 
cytoplasm [13,63]. 
Autophagy is tightly regulated by nutrient sensors such as mTORC1 and AMPK. During the fed 
state, insulin activates mTORC1 which binds and phosphorylates ULK1/2 and consequently, avoids 
autophagy initiation. By contrast, under fasting conditions, mTORC1 is inactivated by AMPK 
triggering autophagy induction by releasing ULK1/2 from mTORC1 [13].  
Even if the most studied participants in autophagy have been referred to in this review, other 
mediators are known to be involved in this process and the detailed autophagy pathway has been 
reviewed elsewhere [63,71].  
4. Autophagy Involvement in WAT Expandability: Clues from Experimental Data 
4.1. Autophagy and White Adipogenesis  
Apart from the well-described role of autophagy as a nutrient provider during energy 
deprivation, autophagy is an essential process for cell remodeling and differentiation [76,77]. In this 
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vein, adipocyte differentiation is highly dependent on autophagy (Figure 1) [76–83]. 10-years ago, 
several authors reported the relationship between autophagy deficiency (i.e., deletion of specific Atg 
genes) and an impairment in white adipogenesis in cellular and animal models [78–80]. Adipocyte-
specific (aP2+ cells) Atg7 knock-out mice showed reduced WAT mass irrespective of diet (control vs. 
high-fat diet) while increasing body insulin sensitivity [78,80]. Similarly, pharmacological inhibition 
of autophagy also led to resistance to high-fat diet-induced obesity and insulin resistance [83]. This 
highlights the relevance that WAT autophagy can have in systemic metabolic regulation and the 
study on the precise mechanisms which link WAT autophagy and white adipogenesis has attracted 
great attention.  
Adipogenesis is a biphasic process by which multipotent, fibroblast-like, adipose mesenchymal 
stem cells (ASCs) are transformed into mature unilocular adipocytes. Mature adipocytes mainly 
consist of an enormous lipid droplet which occupies most of the cytoplasm with the consequent 
removal of a great part of the organelles. Consequently, the cytoplasm of ASCs has to undergo 
profound remodeling. Firstly, fibroblast-like progenitor cells enter the commitment pathway and, 
without morphological modifications, restrict their fate to the adipocyte lineage by giving rise to 
committed preadipocytes. Secondly, preadipocytes differentiate into mature adipocytes [7,27]. 
During the early steps of differentiation, precursor cells undergo a proliferation phase namely clonal 
expansion. In this step, the transcription factor CCAAT-enhancer-binding protein (C/EBP)-β seems 
to be activated and is required for the regulation of mitotic clonal expansion [84,85]. Afterward, 
C/EBPβ is phosphorylated by glycogen synthase kinase-3β (GSK3β) driving the adipogenic process 
forward [86]. C/EBPβ binds to C/EBP regulatory elements in the promoter region of key adipogenic 
transcription factors, i.e., peroxisome proliferator-activated receptor (PPAR)-γ and C/EBPα. These 
two transcription factors induce and maintain the expression of key adipogenic genes such as fatty 
acid-binding protein (FABP)-4, GLUT4, or adiponectin, favoring lipid accumulation into the lipid 
droplet and insulin responsiveness in mature adipocytes [27,87,88].  
As reported by our group and others, the proliferation and differentiation capacities of ASCs are 
compromised in obesity [89–93]. The impairment in ASCs biology is more pronounced in those 
patients with metabolic alterations and abdominal obesity, with differences between fat depots [92–
94]. However, the precise mechanisms underlying these metabolic and obesity-induced changes in 
ASCs are not completely elucidated. Interestingly, it has been described that autophagy is involved 
and gradually induced during adipocyte differentiation (i.e., increasing number of autophagosomes 
in the cytoplasm, higher expression of autophagic markers, e.g., LC3-II, coupled with a suggested 
increase in autophagic flux), which places autophagy as a putative key element for white 
adipogenesis [79,83,95]. Notably, although mature adipocytes were thought to be terminally 
differentiated cells that just undergo changes in their size, recent evidence suggests that they can also 
de-differentiate into fibroblast-like preadipocytes [7,9]. In addition, beige adipocytes, which have 
been proposed to emerge by either differentiation from specific precursors or transdifferentiation 
from white mature adipocytes, can also revert to a white-like adipocyte phenotype (whitening) [9,22]. 
While the role of autophagy in adipocyte dedifferentiation is yet to be determined, evidence shows 
that the whitening program can also be highly regulated by autophagy (Figure 1) [26,96,97]. 
Baerga et al., showed that autophagy deficiency by Atg5 deletion in mouse embryonic fibroblasts 
(MEF) induced for adipogenic differentiation led to an impairment in adipogenesis, specifically in 
the later steps related to morphological modifications, and eventually to cell death. Similar results 
were obtained when wild-type MEFs were treated with the autophagy inhibitor chloroquine [79]. In 
this line, further studies confirmed that autophagy inhibition in 3T3-L1 cells (the most used model 
for adipogenesis [98]) by Atg5 or Atg7 silencing, led to an impairment in triglyceride accumulation 
during adipogenesis, likely as a consequence of the observed reduced expression of adipogenic 
factors (C/EBPα and PPARγ and their targets FABP4, fatty acid synthase (FAS) and stearoyl–
coenzyme A desaturase (SCD)-1). Similar results were seen when wild-type 3T3-L1 cells were 
exposed to pharmacological inhibition (3-methyladenine, ammonium chloride, and leupeptin) of 
autophagy [80,83]. In light of these findings, it was initially thought that autophagy was solely 
involved in late preadipocyte differentiation by enhanced lipid accumulation and favoring the last 
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stage of adipogenesis towards a mature adipocyte. However, the study carried out by Singh et al., 
also revealed that C/EBPβ (involved in preadipocyte clonal expansion and the activation of 
transcription factors required for adipocyte maturation) was downregulated in both Atg5 and Atg7 
deficient 3T3-L1 cells [80]. The effect of autophagy on early adipocyte differentiation was 
corroborated by Skop et al., who found that autophagy inhibition downregulated preadipocyte 
mitotic clonal expansion, and impaired mitochondrial remodeling in 3T3-L1 preadipocytes [95]. 
Even though specific deletion of Atg5 or Atg7, which is supposed to impair autophagy, has been 
related to beneficial metabolic effects, studies on the deletion of other various autophagic genes 
reported opposite effects. Adipocyte-specific p62-deficient mice developed obesity irrespective of diet 
(control diet or high-fat diet), displayed impaired glucose tolerance, and diminished insulin 
sensitivity. In addition, contrary to Atg7-deficient mice, WAT from adipocyte-specific p62-deficient 
mice had greatly enlarged hypertrophic adipocytes as well as higher macrophage infiltration and 
expression of inflammatory markers. Curiously, no changes were reported regarding the expression 
of adipogenic, lipogenic or lipolytic markers. Moreover, there were no signs of enhanced free fatty 
acid mobilization. However, an impaired mitochondrial function on BAT, likely due to decreased 
quality of mitochondria was reported. This was related to an impaired BAT thermogenesis [99]. This 
remarks the importance of the crosstalk between different AT depots in regulating metabolic 
homeostasis. Another in vitro study on Atg16l deletion showed in the same vein, an association with 
impaired insulin responsiveness in MEFs. Impaired insulin sensitivity was due to decreased IRS1 
protein content as a result of enhanced proteasome degradation [100]. Furthermore, mice with Bif1 (a 
positive regulator of autophagosome formation) deficiency were more prone to develop obesity and 
hyperinsulinemia with aging or a high-fat diet. Bif1 deficiency also promoted WAT expansion and 
the presence of hypertrophied adipocytes with decreased lipolytic rate and expression of ATGs [101].  
These discordant findings according to the genetic model of autophagy deficiency give an idea 
surrounding the complexity of the autophagic pathway and its relationship with WAT physiology. 
Because of the pleiotropic role of autophagy regulating different cellular processes, autophagy 
deficiency may have different general consequences depending on the balance of autophagy-
regulated pathways. In addition, non-canonical functions of autophagic genes have been reported 
[102], which could also account for the difference depending on the autophagic gene deleted.  
4.1.1. Mechanisms Underlying the Relationship Between Autophagy and White Adipocyte Biology 
 Autophagic Regulation of Adipogenic Factors 
Although the effect that autophagy deficiency can have on adipogenesis has been reported, 
mechanisms by which autophagy alters WAT physiology are poorly understood. Some studies have 
shown that autophagy can remove specific inhibitory adipogenic factors [83,103]. It has been shown 
that the activation of Atg4b transcription (required for LC3-I formation) by C/EBPβ is required for the 
p62-mediated autophagic removal of krüppel-like factors 2 and 3 (KLF2/3), which are transcriptional 
repressors of Cebpa and Pparg [103]. Also, autophagy prevents proteasome-dependent PPARγ2 
degradation as demonstrated by pharmacological and genetic models of autophagy deficiency [83]. 
These findings suggest a reciprocal regulation of autophagy and adipogenesis and also give 
mechanistic clues on how adipogenesis can be regulated by autophagy. However, not all studies go 
in the same direction. The role of autophagy in limiting the availability of adipogenic activators has 
also been reported. A recent study indicates that GSK3β is sequestrated into late endosomes via-
autophagy with the resulting inhibition of adipogenesis in human subcutaneous preadipocytes [104].  
 Mitophagy 
In addition to the degradation of adipogenic regulators and the consequent modulation of 
adipogenic transcription factors, it has been proposed that autophagy can directly modulate the 
morphological transformation of the fibroblast-like preadipocyte into a mature adipocyte by 
modulating organelle content [26]. Mitophagy, selective removal of mitochondria by autophagy, is a 
relevant player in mitochondrial content modulation as well as in mitochondrial quality control. 
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Mitophagy is induced after mitochondrial depolarization. PTEN-induced putative kinase (PINK)-1 
and Parkin mitophagy pathway is the most characterized mechanism of mitophagy [105]. 
Mitochondrial depolarization leads to the translocation of PINK1 to the outer mitochondrial 
membrane, where it is activated. PINK1 phosphorylates the cytosolic ubiquitin E3-ligase, Parkin. The 
accumulation of ubiquitin chain linkages on the mitochondrial outer membrane as a result of PINK1 
and Parkin action, allows the binding of mitophagy receptors that recognize mitochondrial ubiquitin 
marks (e.g., p62, FUNDC1 or BNIP3). These receptors interact with mitochondria and LIR at the 
nascent autophagosome, so mitochondria is included into autophagosome for lysosomal degradation 
[105,106]. 
Mitophagy has been highlighted as an essential process for white adipogenesis. Evidence have 
shown that adipogenic differentiation is associated with an increase in the number of 
autophagosomes containing mitochondria [81]. Cummins et al., found that, after a high-fat diet, 
adipocytes underwent remarkable metabolic changes prior to WAT macrophage infiltration, 
including loss of mitochondrial biogenesis followed by the downregulation of mitochondrial proteins 
[107]. Besides its role in white adipogenesis, the modulation of mitochondrial content and quality is 
essential for the browning of WAT, as well as for the whitening of beige and brown adipocytes [76,108]. 
Within this context, Taylor et al., observed a downregulation of Parkin-mediated mitophagy during 
the browning of WAT [108]. By contrast, the reversion of beige adipocytes to the non-thermogenic, 
white adipocyte-like state, depends on autophagic mitochondrial removal as demonstrated by 
Altshuler-Keylin et al. Atg5 or Atg12 deletion or pharmacological inhibition of autophagy in animal 
models, promoted UCP1 retention and the maintenance of beige adipocyte characteristics. These 
effects were related to less susceptibility to develop diet-induced obesity (DIO) and insulin resistance 
[109]. In this line, both animal and in vitro models of Atg7 deficiency, showed that Atg7-deficient 
WAT and cultured cells displayed atypical brown-like morphology with high mitochondrial content, 
multilocular aspect with smaller lipid droplets and increased cytoplasm compared to the typical 
unilocular aspect of white mature adipocytes with a single large lipid droplet, few mitochondria and 
scarce cytoplasm [78,80]. A recent study has indeed shown that autophagy inhibition by Atg7 
deficiency prevents glucocorticoid-induced adiposity by suppressing BAT whitening [96].  
High-fat diet consumption is associated with the whitening of BAT together with enhanced 
expression of mitophagy markers [97]. An increased autophagic flux, Parkin and PINK1 expression, 
and the number of mitochondria closely located to autophagosomes, was reported after high-fat diet 
feeding, which suggests that response of WAT to a high-fat diet, at least in part, depends on 
mitochondrial remodeling [107]. Intriguingly, a recent study showed that mice lacking the mitophagy 
receptor Fundc1 developed an impaired response to a high-fat diet with more severe obesity and 
insulin resistance, and more infiltration of proinflammatory macrophages [106]. This could be, at 
least in part, because mitophagy is also required for maintaining proper mitochondrial function and 
avoiding cell dysfunction [105]. Thus, beyond the relationship with brown/beige adipocyte 
functioning, changes that white adipocytes undergo in order to adapt to a high-fat diet consumption, 
are also closely related to mitochondrial homeostasis and especially to mitophagy.  
Recent evidence suggests that mitophagy can be involved in the activation of cellular senescence 
in adipocyte precursors cells as well as in mature adipocytes. WAT senescence is a feature of obesity-
associated metabolic disturbances [110] and autophagy has been found to be increased in senescent 
cells [111]. The accumulation of senescent cells in WAT impedes tissue renewal [112]. sWAT 
progenitor cells from obese and/or diabetic subjects showed a diminished ability to differentiate into 
mature adipocytes, which was associated with the induction of the senescence activators p53 and p16 
[113]. Then, senescent progenitor cells have an impaired differentiation capability. In this vein, 
activation of p53 results in defective adipogenesis in stromal vascular fraction (SVF), while p53 down-
regulation in MEFs or 3T3-L1 cells enhanced adipocyte differentiation and increased mitochondrial 
content [114,115]. However, whether autophagy and more precisely, mitophagy, is involved in these 
phenomena remains unsolved. On the other hand, activation of p53 also results in senescent mature 
3T3-L1 adipocytes [110,113], while p53 genetic ablation in mature adipocytes favored the beiging of 
sWAT by a reduction in mitophagy and increased number of mitochondria [116]. Thus, autophagy 
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may also be involved in regulating adipocyte senescence which alters WAT plasticity and 
adipogenesis, and has serious consequences for metabolic health [110,117]. However, to date, the 
evidence regarding this issue remains scarce and further studies should be performed to clarify it. 
 Lipophagy 
Lipophagy is the selective degradation of lipid droplets. It has been extensively studied in 
hepatocytes but also occurs in other cell types. In comparison with mitophagy, selective receptors for 
lipophagy have not been found [48]. Although the role of lipophagy in white adipogenesis is not yet 
understood, a recent study has pointed out that mTORC1 inhibition led to autophagic sequestration 
and lysosomal degradation of lipid droplets as well as lipolysis upregulation in vivo and in primary 
adipocytes [118]. As detailed in Section 3, activated mTORC1 represses autophagy. Regulatory 
associated protein of MTOR complex (RPTOR)-1 is required for mTORC1 activation and autophagy 
inhibition. Adipose-specific deletion (adiponectin-positive cells) of Rptor1, and consequently 
inhibition of mTORC1, promoted adipose lipophagy and affected adipocyte morphology with 
reduced lipid droplet size. The authors also concluded that this effect occurred in terminal phases of 
adipogenesis rather than early stages of differentiation and was accompanied by the downregulation 
of the adipogenic markers PPARγ and perilipin (PLIN)-1 [118]. When the effects of Atg7 deficiency 
on lipophagy were analyzed, a decrease in the number of lysosomes containing lipid droplets was 
found, however, with a downregulation of adipogenic markers. Interestingly, Atg7- Rptor1 double 
knock-out mice recovered WAT development and upregulated thermogenic gene expression in BAT 
compared to Rptor1 knock-out [118]. 
These results highlight the complexity of adipogenic regulation by autophagy machinery, 
suggesting that other mechanisms than the autophagy pathway may be participating. In fact, 
previous studies described that mTORC1 repression (by either genetic ablation or by rapamycin) led 
to adipogenesis inhibition [82,119–121], similarly to Atg5 and Atg7 deficiencies [78–80], and was 
associated with decreased weight and enhanced mitochondrial respiration [119]. The explanation 
proposed for these contradictory results was the pleiotropic role that mTORC1 has beyond 
autophagy regulation (e.g., stimulation of anabolic pathways including protein, lipid, and nucleotide 
synthesis which allows cell growth) [122]. However, it is yet necessary to confirm whether the effects 
of mTORC1 deletion on adipose biology are due to autophagy induction, another mTORC1-regulated 
pathway, or both [11]. Regardless, the study by Zhang et al., confirmed that mTORC1 deletion has a 
direct effect on adipose lipophagy [118]. Evidence from human studies showed that the lipid droplet 
marker perilipin, colocalized with autophagic marker LC3 in subcutaneous adipocytes and that the 
occurrence of lipid droplet-containing autophagosome was higher in adipocytes from diabetic 
patients concomitantly with an attenuated mTOR expression. In view of these results, the authors 
hypothesized that lipophagy could be taking part in adipocyte lipolysis [123]. 
Contradictory evidence regarding the way in which autophagy affects adipocyte biology 
depending on the autophagy-related molecule analyzed, bring to light the complexity of this 
regulatory interplay and suggest that each participant can drive adipocyte differentiation and 
function in opposite ways, likely by both dependent- and independent-autophagy pathways. It is 
worth mentioning that most studies have focused their attention on adipocyte development, but few 
have been aimed at studying the crosstalk between autophagic mediators and mature adipocyte 
functioning. A recent study analyzed the effect of autophagy ablation by specific adipose deletion of 
Atg3 and Atg16l in mature adipocytes. By using Cre-loxP recombination in vivo [124], the authors 
induced Atg3 or Atg16l depletion at 8-weeks of age. Contrary to adipose-specific congenital Atg5 or 
Atg7 genetic deletion, postnatal Atg3 or Atg16l deletion provoked peripheral insulin resistance 
regardless of diet or fat mass [125]. All this evidence remarks that autophagy can also be dependent 
not only on cell or tissue type, but also on the stage of differentiation or the cellular functional state, 
which would difficult the use of autophagy modulation as a therapeutic option.   
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Figure 1. Autophagy modulates white adipogenesis. Autophagy is induced during adipogenesis. 
Genetic and pharmacological inhibition of autophagy has been shown to repress early and late 
adipogenesis. Similarly, mitophagy is required for whitening of beige adipocytes. In fact, autophagy 
inhibition maintains beige phenotype. Despite most of the studies suggest that autophagy promotes 
adipogenesis and the white adipocyte phenotype, others have found opposite evidence, e.g., 
autophagic removal of adipogenic activators such as GSK3β or lipophagy activation by mTORC1 
inhibition, which results in impaired lipid accumulation in terminal phases of adipogenesis together 
with PPARγ downregulation. Here we present an overview of the evidence relating autophagy with 
white adipogenesis. Reddish elements depict negative effects on adipogenesis, while green elements 
favor white adipocyte formation. 
4.2. Autophagy and Extracellular Matrix Regulation: Implications for WAT Remodeling  
WAT expansion and remodeling to store excess energy or to mobilize lipids in the case of 
nutrient deprivation is not only dependent on adipocytes themselves, but also depends on the 
extracellular environment that surrounds adipocytes and its precursors, which determines the 
physical space to grow in size and number. ECM, a complex three-dimensional protein network, 
constitutes the microenvironment that physically supports tissue-resident cells and maintains tissue 
structure [126,127]. ECM is mainly composed of fibrillary proteins such as collagens or elastin, and 
glycoproteins such as proteoglycans, fibronectin, or laminin, which altogether represent the core 
ECM [126]. Besides the core ECM, there are also a variety of ECM-associated proteins embedded in 
the ECM that modulates its composition by promoting degradation or deposition of core ECM 
components or controlling the interaction between ECM components [126–130].  
The composition and spatial organization of the ECM define its degree of flexibility, establishing 
physical limits for cells to proliferate, to modify their shape and/or to grow. Moreover, cells 
(including adipocytes) respond to mechanical cues by activating different signaling pathways to 
modulate their physiology [40,131]. ECM also modulates the availability of soluble molecules such 
as growth and angiogenic factors, chemokines, or enzymes [127]. Furthermore, most of the ECM 
components interact with cells via integrin, activating intracellular signaling cascades, and 
connecting ECM with the cytoskeleton, which results in modulation of cell activity and motility [126]. 
Then, ECM not only provides mechanical stimuli, but it also controls cell activity and phenotype by 
modulating signals for cell survival, proliferation, differentiation, and motility [126,132]. ECM is such 
a relevant component for healthy WAT remodeling, that fibrosis (abnormal deposition and 
organization of ECM components) has been defined, together with inflammation and hypoxia, as one 
of the hallmarks of dysfunctional WAT [28,133]. Notably, ECM stiffness, defined by the composition 
and organization of fibrillary ECM components, reciprocally depends on cell production of ECM-
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core components as well as ECM-associated and ECM-modifying factors [40,94,134,135]. Therefore, 
proper regulation of ECM synthesis and degradation pathways is essential for maintaining healthy 
WAT remodeling. Major ECM-producing cells in WAT include fibroblast, myofibroblast, adipocyte 
precursors, mature adipocytes, and macrophages [40].  
There are a number of studies that have shown the involvement of autophagy in fibrotic 
processes of several tissues and organs such as the liver, kidney, heart, cartilage, or pancreas [136–
140]. Several studies have given clues regarding the modulation of fibroblast biology and the 
differentiation into profibrogenic myofibroblast by autophagy [141]. The relationship between ECM 
and autophagy is bidirectional: autophagy can modulate the synthesis and degradation of ECM 
components by tissue-resident cells, but ECM can also modify the autophagic cell response [140,142–
146]. However, this relationship between ECM and autophagy has been poorly explored in WAT. 
One of the latest studies in WAT autophagy has reported the relationship between the autophagic 
pathway and the fibrogenic response of adipose precursors to a high-fat diet. For this purpose, 
Pdgfra-CreErt2 transgenic mice were used for generating conditional deletion of Atg7 in adipocyte 
progenitor cells [147]. PDGFRα positive cell population (referred to as fibro/adipogenic progenitors 
due to their dual potential toward either fibroblast, white adipocyte, or beige adipocyte 
differentiation [148–151]), has been shown to be central for WAT fibrosis. Knock-out mice showed a 
decrease in the WAT expression of ECM components as well as in the fibrosis score (determined by 
collagen deposition) in response to a high-fat diet compared to control mice. These changes were 
independent of fat mass, adipocyte cell number or the inflammatory response. In vitro analyses 
suggest that the attenuation of WAT fibrogenic response to a high-fat diet is mediated by an alteration 
in the expression of components of the TGF-BMP signaling pathway [147]. Furthermore, the authors 
found signs of WAT beiging in Atg7 knock-out mice which inversely correlated with the expression 
of different collagen subtypes [147]. Decreased WAT fibrosis due to Atg7 deficiency could partly 
explain the previous evidence of metabolic health in adipose-specific Atg7 knock-out mice despite an 
impaired adipogenesis [78,80].  
Results from this study suggest that autophagy deregulation might also be involved in WAT 
fibrosis. However, previous evidence has shown contradictory results depending on which 
autophagy molecule is deleted [80,99,101], therefore further studies should be performed in order to 
elucidate the precise mechanisms and autophagic mediators involved in the fibrogenic WAT 
response. In addition, the differential relationship between autophagic and ECM synthesis and 
degradation pathways depending on the WAT cell type analyzed should not be ruled out.  
4.3. Autophagy and WAT Inflammation 
Autophagy has been closely related to innate and adaptive immunity, not only by eliminating 
pathogens, but also by modulating immune cell functions such as antigen presentation, development 
and maintenance of immune cells, and cytokine production and secretion in both immune and non-
immune cells [152,153]. In this regard, autophagy functions as a protective mechanism against 
infections but also against the host’s excessive response by participating in immunological tolerance 
and the negative regulation of the immune response [154]. In agreement with the well-known 
function that autophagy has in degrading pathogens (xenophagy), activation of pattern recognition 
receptors (PPRs), such as toll-like receptors (TLRs) or nucleotide oligomerization domain (NOD)-like 
receptors (NLRs), which recognize and bind to microbial components (i.e., pathogen-associated 
molecular patterns (PAMPs)) or damage-associated molecular patterns (DAMPs) resulting from 
endogenous damage, trigger autophagy (and more specifically, xenophagy) by recruiting various 
ATGs proteins, as reviewed elsewhere [155,156]. Conversely, once triggered, autophagy negatively 
regulates inflammation by inhibiting cytokine secretion and production (e.g., IL1β, IFN1), by IL1β 
degradation in the autophagosome and by directly inhibiting the inflammasome. In addition, the 
inflammasome is indirectly down-regulated by autophagy due to diminished IL1β availability [155–
157]. In this manner, autophagy restrains the inflammatory response that otherwise may cause 
serious complications, including septic shock, allergies, or metabolic disorders [155].  
Metabolites 2020, 10, 179 12 of 30 
 
Although this is the general outline of the relationship between autophagy and immunity, there 
are some controversial research findings. For instance, it has also been reported that NLRs can inhibit 
autophagy by interacting with Beclin-1 [158] and that inflammatory stimuli (i.e., lipopolysaccharides, 
LPS) lead to supposed autophagy impairment in bone marrow-derived macrophages determined by 
the qualitative increase in p62 protein levels that were explained by the authors as protein 
accumulation due to diminished lysosomal p62 degradation [159]. Moreover, the regulation of 
autophagy by cytokines has been described, though stimulation or inhibition is dependent on the 
precise cytokine and the tissue of action [154,160]. Thus, there are still some unresolved issues 
regarding how the crosstalk between these two processes takes place. The implication of autophagy 
in immune response has not only been related to infectious diseases, but also to chronic inflammatory 
diseases such as metabolic disorders [154]. Within this context, the role of autophagy in the low-grade 
inflammatory state of WAT has drawn attention. 
WAT malfunction is characterized by chronic low-grade inflammation with an increased 
infiltration of immune cells, especially macrophages. Under pathological conditions, WAT 
accumulates a higher number of apoptotic adipocytes which favors macrophage infiltration and 
inflammation. Moreover, as mentioned above, hypertrophic adipocytes display oxidative and ER 
stress, leading to the activation of inflammatory cascades and the release of proinflammatory 
cytokines that attract more immune cells [22,42,133,161]. Recruited monocytes polarize to a M1-like 
pro-inflammatory phenotype (“classically activated macrophages”) at the expense of diminishing 
M2-like anti-inflammatory macrophages (“alternatively activated macrophages”) which contribute 
to WAT homeostasis [135,162]. Inflammatory mediators disrupt insulin signaling, which impairs 
even more WAT function. What is more, WAT releases pro-inflammatory molecules into the 
circulation which promote systemic insulin resistance and impairs cardiovascular function [39,41]. In 
addition to WAT insulin resistance, inflammation is related to the fibrotic process. Fibrosis is part of 
the inflammatory response for injured tissue regeneration. However, it has to revert once the damage 
has been repaired. Otherwise, tissue dysfunction due to increased fibrosis would develop [133]. 
Macrophages modulate ECM composition and it has been suggested that M2-like macrophages 
participate in healthy ECM remodeling [163].  
In this scene, macrophage autophagy, which has been implicated in macrophage polarization 
and function, may be playing a relevant role in WAT immunological homeostasis. Macrophage-
specific Atg7 deletion promoted the shift to the M1-like phenotype. When exposed to a high-fat diet, 
macrophage-specific Atg7 knock-out mice showed higher WAT macrophage infiltration and 
proportion of M1-like proinflammatory phenotype compared to wild-type mice, as reflected by the 
increase in M1-like and reduction in M2-like macrophage markers. Though no significant differences 
in weight were found, macrophage-specific Atg7 knock-out mice displayed impaired systemic insulin 
sensitivity. Autophagy blockage was also associated with elevated macrophage reactive oxygen 
species (ROS) and IL1β secretion in vitro [159]. Therefore, autophagy deficiency seems to promote 
the proinflammatory response of WAT macrophages. Studies on macrophage-specific Atg5 knock-
out mice revealed similarities in macrophage polarization towards a pro-inflammatory M1-like 
phenotype. However, contrary to Atg7 macrophage deficiency, no effect was seen in WAT 
inflammation in Atg5 or Atg16l macrophage-deficient mice [164,165]. This points out the differences 
between genetic models of autophagy deficiency and the putative disparate roles of ATGs in 
regulating other processes than autophagy according to tissue type. Notwithstanding, a recent study 
that focused on WAT macrophage autophagy reported that LC3 content was higher in WAT 
macrophages from genetically obese mice compared to lean mice. In addition, results from this study 
suggest that the WAT microenvironment is able to influence resident macrophages by enhancing 
autophagic flux. Unfortunately, the inflammatory profile of these macrophages were not determined 
[166]. Assuming that WAT from genetically obese mice is inflamed [167], these findings may be 
somewhat puzzling if it is considered that autophagy dampens the inflammatory response. 
Metabolic endotoxemia, i.e., high circulating LPS levels due to increased translocation from the 
gut into the circulation, might be one of the pieces to solve this puzzle. Besides the well-accepted 
concept that WAT dysregulation contributes to systemic inflammation and metabolic disruption, it 
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has also been proposed that external stimuli can trigger WAT inflammation. Apart from the 
detrimental effects of elevated nutrient consumption which can impair metabolic function (e.g., 
saturated fatty acids or excess glucose), nutritional stress can promote a low-grade systemic 
inflammatory state by enhancing the translocation of bacterial products, such as LPS, from the gut to 
the circulation [168]. Consumption of high-fat meals has been shown to especially enhance LPS 
translocation as these molecules bind to chylomicron during lipoprotein particle assembly in 
enterocytes [169]. Moreover, modulation of the gut microbiota composition by detrimental dietary 
compounds such as saturated fatty acids, leads to gut barrier dysfunction with increased gut 
permeability favoring more LPS translocation [170]. The increased levels of circulating LPS from gut 
microbiota related to nutritional stress and metabolic status has been named as “metabolic 
endotoxemia” [168]. It has been proposed that LPS could bind to TLRs in WAT cells and trigger 
adipocyte dysfunction and inflammation. In this vein, our group has recently demonstrated that 
metabolic endotoxemia is directly related to human adipose dysfunction and inflammation and that 
low LPS concentrations directly affect the function of human adipocytes [171]. 
Taking into consideration that TLRs activate autophagy, this could account for the increased 
autophagy in WAT during the obese state and metabolic disruption [172–175]. In keeping with this 
hypothesis, Atg16l deficiency was associated with exacerbated IL1β production upon LPS stimulation 
[157], suggesting that the inflammatory response in obesity could be even worse in the case that 
autophagy would not be up-regulated. In fact, ex vivo autophagy inhibition in human or mouse WAT 
explants from healthy lean subjects/animals led to an increase in gene and protein expression of 
proinflammatory cytokines [172]. 
Accordingly, the protective role of WAT autophagy in obesity against the inflammatory 
response, a parallel increase in autophagy and proinflammatory cytokines, and macrophage 
infiltration in obese subjects compared to normoglycemic lean individuals has been described [174]. 
Intriguingly, in vitro studies revealed that hypertrophic 3T3-L1 adipocytes had diminished 
autophagy but increased inflammation. This inverse relationship was confirmed by autophagy 
induction with rapamycin (inhibitor of mTOR), which reduced the expression of inflammatory 
cytokines as well as by autophagy inhibition with lysosomal blocking agents which enhanced the 
expression of inflammatory cytokines [176]. These findings highlight the reciprocal regulation 
between autophagy and inflammation in WAT. However, the precise mechanisms and molecular and 
cellular players implicated in the crosstalk between inflammation and autophagy and how this can 
influence WAT adaptation to nutritional stress remains to be investigated.  
5. WAT Autophagy Status in Obesity and Diabetes: Evidence from Animal and Human Studies 
Most of the evidence regarding the systemic metabolic consequences of disrupted autophagy in 
WAT comes from animal studies. Animal models of adipose-specific deletion of autophagic genes 
have demonstrated that WAT dysregulation due to impaired autophagy has serious consequences in 
systemic metabolic regulation. On the one hand, Atg5 or Atg7 knock-out mice were resistant to diet-
induced weight gain with reduced white adipogenesis, but improved insulin sensitivity and reduced 
leptin levels [78,80]. If considered that adipogenesis is the way of WAT to healthily expand (as 
described in Section 2), the positive metabolic characteristics of these mice seem to be contradictory 
at first sight. However, the metabolic effects of Atg5 or Atg7 deletion might be mediated, at least in 
part, by the increase in lipid β-oxidation and browning of WAT [78,80] as well as by decreased fibrosis 
[147], which would explain the healthy metabolic profile despite decreased WAT adipogenesis. 
Another issue to be mindful of is that other studies on autophagy deficiency that targeted different 
autophagic genes (see Section 4.1), found opposite results with detrimental effects on adiposity and 
metabolism [99–101]. Despite the valuable knowledge obtained from animal models of adipose-
specific autophagy deficiency, it remains unclear how the global autophagic process is modulated in 
obesity and metabolic diseases.  
Direct exploration of WAT autophagic status in relation to metabolic diseases is required for 
elucidating the actual mechanisms underlying the development of WAT malfunction related to 
obesity and metabolic dysregulation. In this vein, high-fat diet-induced obese mice had impaired 
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autophagy in WAT [176–178]. More specifically, increased LC3-II and p62 protein levels in vWAT in 
DIO mice were reported, while ATG5 or Beclin-1 levels remained unchanged. Determination of 
autophagic flux in vWAT explants from DIO mice suggested an enhanced formation of 
autophagosomes, but impaired lysosomal function in obese vWAT [177]. Another study reported 
total autophagic suppression in high-fat diet-induced obese mice without LC3-II detection by 
immunofluorescence [176]. Curiously, Nuñez et al., described diminished levels of phosphorylated 
mTOR together with increased Beclin-1 but also increased p62 levels in DIO mice compared to their 
lean counterparts [178]. Therefore, if results regarding LC3 and p62 are considered, evidence heads 
in the same direction (attenuated autophagy in high-fat diet-induced obesity). These discordant 
findings regarding LC3-II, beclin-1, or phosphorylated mTOR levels are remarkable.  
Another relevant issue is the precise step of the autophagic process which is affected during 
DIO. The study by Yoshizaki et al., suggested that autophagy is impaired from the early stages 
affecting autophagosome formation in DIO mice, as LC3-II (mainly degraded by lysosomes) did not 
accumulate after lysosomal inhibition [176]. By contrast, Mizunoe et al., reported an increased 
autophagosome formation induced by high-fat diet, but increased LC3-II and p62 (almost exclusively 
degraded by lysosomal pathway) after lysosomal inhibition. However, protease lysosomal 
dysregulation was seen, which suggests that only the latest step of autophagy might be attenuated in 
DIO animals [177]. These differences, similarly to other controversial studies, might be due to the 
different experimental approaches, highlighting the need for unifying criteria for the determination 
of the autophagic status [179]. Another issue could be differences in dietary intervention as the 
duration of the high-fat diet differed among the studies, suggesting a time-dependent adaptation in 
the autophagic response to nutritional stress [176–178]. It is also remarkable that there is a discordant 
interpretation by authors concerning the autophagic status in the different studies, e.g., increased 
levels of p62 are regarded as either attenuated [177] or enhanced autophagy [178], which makes it 
more difficult to draw clear conclusions.  
Regarding human studies, the general depicted trend is an increased WAT autophagy in obese 
and/or diabetic subjects (Table 1) [123,172–175,178,180,181]. It was independently found that higher 
mRNA and/or protein levels of several autophagic markers (Beclin-1, ATG5, ATG12, ATG7, LC3A 
and B, LC3-II, p62) and decreased mTOR expression in sWAT and/or vWAT from obese patients 
compared with lean individuals [123,172–175,178,180]. Notably, not all studies analyzed the same 
molecules and some of the markers, independently analyzed in the different studies, were not equally 
upregulated in every study or in each fat depot, which could be due to differences in study 
population characteristics. Taking into account the discordant findings regarding autophagy status 
in WAT from DIO mice and obese subjects, some authors aimed at confirming whether the 
autophagic flux was increased concomitantly to gene/protein expression of autophagy markers. 
Baseline accumulation of some autophagic proteins involved in cargo recognition and 
autophagosome formation, such as LC3 or p62 (almost exclusively degraded via lysosomes), could 
be indicative of two inverse situations: (1) increased autophagy flux or (2) impaired lysosomal 
degradation that leads to the accumulation of autophagosomes and associated proteins. Autophagic 
flux assays allowed to discern between these two situations [179]. To this end, in vitro experiments 
have been performed in the presence of lysosome inhibitors, finding that sWAT and vWAT explants 
from obese subjects and DIO mice had an enhanced autophagic flux and indicating concordant 
results with WAT gene or protein expression in obesity [173,177].   
As WAT is composed of different cell types, it was raised whether the described alterations in 
total WAT autophagy from obese and diabetic individuals were due to adipocytes per se or to other 
WAT-resident cells such as macrophages (see Section 4.3). Then, several studies have analyzed 
autophagy in mature adipocytes vs. stromal vascular fraction (SVF) containing WAT resident cells 
other than mature adipocytes [172,173,180]. Although the different studies demonstrated the 
autophagy expression in mature adipocytes, it was not clear which fraction may contribute more to 
total WAT autophagy and differences between SVF and adipocytes were dependent on the 
autophagy-related gene measured.  
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Table 1. Human studies analyzing autophagy state in obesity and/or diabetes. 
Study 
[Reference] 
Design WAT Depot 






Öst et al. 
[123]  
Study groups: 
(1) T2D and BMI > 27kg/m2 (n 
= 7) vs. 
(2) Non-T2D (non-BMI 
matched) (n = 7) 
Subcutaneous - Isolated 
adipocytes 
- TEM  
- Immunofluorescence 
- Immunoblotting  





T2D led to:  
- ↑ autophagosome number 
(TEM). 
- ↑ autophagic flux 
(accumulation of LC3).  
- ↓ lipofuscin particles. 
- = mTOR protein expression.  
Kovsan et al. 
[173] 
Cohort 1:  
Non-obese  
(BMI < 30; n = 15) vs. Obese  
(BMI > 30; n = 50) 
Cohort 2:  
Lean  
(BMI < 25; n = 66); 
Subcutaneous obesity (BMI > 
30; n = 88) vs. Visceral obesity  
(BMI > 30; n = 42). 
Cohort 3:  
IS obese  
(BMI > 40; n = 30) vs.  
IR obese  
(BMI > 40; n = 30) 
-Subcutaneous  
-Visceral 
- Total tissue 
- Explant (n = 1 
Ow) 
- SVF and 
adipocytes (only 
vWAT) (n = 24). 
- Real-time qPCR 
- Immunoblotting  
- Immunofluorescence 
(explant). 











- ↑ ATG5 & LC3- II protein 
expression in vWAT vs. sWAT 
in obesity. 
- ↑ ATG12-ATG5 complex 
protein expression in vWAT vs. 
sWAT, regardless of BMI. 
- ↑ ATG5 and LC3B mRNA 
levels in vWAT vs. sWAT.  
- ↑ mRNA ATG5, LC3A and 
LC3B levels in obese vs. lean. 
- ↑ mRNA ATG5, LC3A and 
LC3B levels in IR obese vs. IS 
obese.  
mRNA/protein levels of ATG5, 
LC3B/LC3-II higher in 
adipocytes vs. SVF. 
Explant: 
- ↑ LC3-positive dots vWAT vs. 
sWAT. 
- ↑ autophagic flux in obesity 
(p62 accumulation). 
   
Jansen et al. 
[172] 
 
Study groups:  
(1) Obese  
(BMI = 27–35; n = 16) 
- Subcutaneous 
- Visceral 








- ↑ LC3-II in obesity. 
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(2) Lean  
(BMI = 20–25; n = 17) 
 
- Positive correlation between 
LC3-II levels and BMI, HOMA-
IR, macrophage infiltration. 
Explant (vWAT & sWAT): 




A. et al. 
[180] 
Study groups:  
(1) NG Lean  
(BMI < 25; n = 55) 
(2) NG Obese (n = 66)* 
(3) IGT Obese (n = 37) * 
(4) T2D Obese (n = 36)* 
* Obese: BMI ≥ 30 
 
- Visceral - Total tissue  
- Adipocytes 
- SVF 






Total vWAT:  
↑ BECN1 and ATG7 mRNA 
levels in T2D Obese vs. NG lean 
and obese.  
Adipocytes vs. SVF: 
No significant differences.  
Adipocytes:  
- ↑ BECN1, ATG5 and ATG7 
mRNA levels upon TNFα 
stimulus. 
- ↓ ATGs mRNA upon acylated 
ghrelin stimulus. 
Nuñez, C.E 
et al. [178] 
 
Study groups:  
(1) Non-T2D obese  
(BMI = 43 ± 4.3; n = 9)* 
(2) T2D  
(BMI = 32 ± 2.2; n = 6)* 
(3) Lean control  
(BMI = 23 ± 2.7; n = 8) 
* Prospective follow-up  
~1 year after surgery 
Subcutaneous  - Total tissue 
- Explant  
- Immunoblotting 
 - TEM 
Beclin 
Autophagosome 
- ↑ Beclin in obese groups vs. 
lean group.  
- ↓ Beclin after surgery (non-
differences between T2D and 
non-T2D). 
- ↓ autophagosome after 
surgery.  
Kosacka, J. 
et al. [174] 
Study groups: 
(1) Lean (BMI < 25; n = 20). 
(2) Non-T2D Obese (BMI > 30; 
n = 20). 








- Real-time qPCR 
- TEM 
 








General trends:  
- gradual increase in LC3, ATGs 
& p62 from group (1) to (3) in 
vWAT and sWAT. 
- Parallel increase in 
inflammatory and caspase-
dependent apoptotic markers. 
- Higher number of 
autophagosomes in obese vs. 
lean. 
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Soussi, H. et 
al. [181] 
Study groups: 
(1) Lean (BMI = 20–23; n = 12).  
(2) Obese (BMI = 34–79; n = 
24).  
* Subcohort from group 2: 
Obese for bariatric surgery 






- Real-time qPCR. 
- Immunoblotting. 
- Autophagic flux. 
LC3-I & II 
p62 
- ↑ p62 mRNA and protein 
levels in obesity. 
- ↓ absolute LC3-II levels in 
obese vs. lean after lysosomal 
inhibition. 
- ↑ absolute LC3-II levels post-
surgery vs. pre-surgery after 
lysosomal inhibition. 
Xu, Q. et al. 
[175] 
Study groups: 
(1) Ow/Obese patients (BMI > 
25–41.7; n = 17) with or 
without IGT. 
(2) NG lean (BMI ≤ 25; n = 9). 
- Subcutaneous 
 








- Real-time PCR 





ATG 5, 7 & 12 
LC3A-B 
Protein: 
LC3-I & II 
p62 
Total sWAT: 
↑ ATGs mRNA levels in 
Ow/obese group. 
Adipocytes:  
↑ LC3-II and = p62 protein 
levels after lysosomal and 
lipolysis inhibition vs. non-
lipolysis inhibition.  
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To be more precise, Kovsan et al., found higher ATG5, LC3A, and LC3B gene expression and 
LC3-II protein levels in visceral mature adipocytes than in SVF, although the donor phenotype is 
elusive [173]. Jansen et al., replicated the findings regarding ATG5 and also saw that ATG7 followed 
a similar trend in SVF and adipocytes from both sWAT and vWAT of healthy individuals. However, 
when analyzing other ATGs, i.e., ATG1 and ATG16L, an opposite trend towards lower expression in 
mature adipocytes than in SVF was found [172]. By contrast, Rodriguez et al., did not find any 
significant differences between visceral adipocytes and SVF from obese subjects in Beclin-1, ATG5, 
or ATG7. Despite not being statistically significant, ATG7 showed a trend towards higher expression 
in SVF than in adipocytes [180]. In view of these disparate results, no clear conclusion can be made 
regarding which WAT cellular fraction is more involved in total tissue autophagy or about the 
coordinated autophagic response of the different WAT cell populations to nutritional stress or 
metabolic signals in human obesity.  
Notably, none of the studies compared these two fractions according to the obesity degree or 
glycemic status. However, several studies did analyze autophagy in isolated adipocytes regarding 
obesity or the glycemic status [123,181]. Öst et al. found that subcutaneous adipocytes from diabetic 
obese patients compared to non-diabetic individuals (non-BMI matched) displayed attenuated 
mTOR expression concomitant to an increase in autophagic activity determined by autophagosome 
quantification, LC3 immunofluorescence and autophagic flux assay [123]. Conversely, Soussi et al. 
described the basal accumulation of p62 in obese subcutaneous adipocytes compared to lean 
adipocytes, but when assaying the autophagic flux, no changes in LC3 accumulation was seen, 
indicative of an already altered autophagic clearance in obesity [181]. The different group 
classification criteria in each study might be an explanation for discrepant results as the former 
prioritized the glycemic status whereas the latest, the obesity degree. This is indicative that glycemic 
status may be influencing WAT autophagy besides BMI. In fact, despite the established associations 
between the WAT expression of autophagic factors and obesity, it should be kept in mind that the 
discordant phenotypes regarding the obesity degree and the metabolic status (e.g., the metabolically 
healthy obese and metabolically unhealthy lean individuals) have yet to be studied. These 
phenotypes remark that the expansion capacity of WAT, rather than its size, would determine the 
development of metabolic alterations (see Section 2), and regulatory pathways involved in the WAT 
expandability are of relevance in determining metabolic health. As discussed throughout this review, 
autophagy is crucial in many of the processes required for healthy WAT expansion, so it is of great 
interest to gain insight into autophagic status according to the metabolic health of the individual. In 
this regard, few human studies have compared diabetic and/or insulin-resistant patients with 
normoglycemic subjects, finding an increased expression of autophagic factors in the former group 
[123,173,174,180]. Notably, only obese subjects with impaired glucose metabolism have been studied, 
hence it remains unknown whether metabolic alterations and more specifically glucose homeostasis, 
could per se drive dysregulated WAT autophagy. Some findings suggest that the glycemic status 
could have more weight than obesity as only T2D obese significantly differed from normoglycemic 
leans, normoglycemic obese and insulin-resistant obese participants, without significant differences 
between normoglycemic lean and normoglycemic obese subjects [180]. By contrast, others found a 
progressive augment of WAT autophagy from normoglycemic leans, non-diabetic obese, and T2D 
obese subjects [174]. Therefore, further in-depth studies with thorough patient phenotyping are 
needed to clarify this issue. In any case, it seems that altered autophagy in WAT is associated with a 
poorer metabolic profile as mRNA and/or protein levels of autophagic markers in sWAT or vWAT 
have been positively correlated with plasma triglycerides, cholesterol, free fatty acid, leptin levels 
and HOMA-IR, but negatively with adiponectin levels [172,173].  
Given that the development of obesity-related comorbidities is more closely associated with 
central obesity (i.e., increased vWAT) than to peripheral obesity (i.e., increased sWAT), it is of interest 
to explore how autophagy is differentially altered in vWAT and sWAT during obesity. Kovsan et al., 
faced this issue and found that patients with intra-abdominal fat accumulation tended to have higher 
mRNA levels of ATG5, LC3A, and LC3B than patients with peripheral obesity. Accordingly, the 
authors reported augmented gene and protein expression of autophagic markers in vWAT vs. sWAT 
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regardless of BMI or glycemic status [173]. Central obesity is typically related to hypertrophic and 
deleterious WAT expansion [90] as hypertrophied adipocytes have been associated with an impaired 
metabolic status (discussed in Section 2) [4,7,9,42]. In view of the association of dysregulated WAT 
autophagy with central obesity, several studies have analyzed the relationship between WAT 
autophagy and adipocyte cell size in obesity [173,175,181]. In agreement with the notion of increased 
autophagic flux under detrimental metabolic conditions, the expression of autophagic factors has 
been positively correlated with adipocyte size [173,181]. However, this was not confirmed by all the 
studies, with no significant correlation with adipocyte autophagic flux [175]. Methodological 
differences might account for these differences, and further studies should be performed to shed light 
on the relationship between autophagy and the promotion of adipocyte hypertrophy.  
Local and systemic low-grade inflammatory state is another hallmark of metabolic 
dysregulation [28,169,171,182]. It has been reported that autophagy inhibition in WAT or adipocytes 
triggers the inflammatory response (detailed in Section 4.3) [172,176]. These findings are challenging, 
taking into consideration that human obesity has been associated with higher autophagic expression 
in WAT. It has indeed been described that the enhanced expression of autophagic genes in sWAT 
and vWAT from obese subjects occurred in parallel with enhanced protein levels of proinflammatory 
cytokines and macrophage infiltration [174]. Increased LC3-II protein levels have been positively 
correlated with macrophage infiltration [172]. Notably, it remains unknown whether the enhanced 
LC3-II expression in these studies is due to enhanced autophagic flux or impaired lysosomal 
degradation. Some authors have hypothesized that the up-regulated autophagy in obesity (and/or 
insulin-resistant or diabetic states) is triggered as a protective mechanism against WAT inflammation 
[172], which would explain the putative controversial results. However, it should be also regarded 
that some models of ATG deficiency were protected from insulin resistance [78,80]. Another 
proposed hypothesis is that autophagy-independent pathways might be also modulating the 
inflammatory response [174].  
The effect of weight-loss interventions on human WAT autophagy has also been studied, 
supporting the hypothesis about enhanced autophagy in obesity [178,183]. Nuñez et al., analyzed the 
expression of Beclin-1 in sWAT from obese patients before and 1 year after bariatric surgery, finding 
a significant reduction irrespective of the presence of diabetes. Beclin-1 expression levels after surgery 
were similar to those from non-diabetic lean subjects. Beclin-1 expression decrease was accompanied 
by a reduction in the autophagosome number [178]. Hence, it can be postulated that metabolic 
improvement after bariatric surgery comes together with sWAT autophagy attenuation. Conversely, 
Soussi et al., indicated an impaired autophagic flux in adipocytes from obese patients which recovers 
after bariatric surgery [181]. However, it is worth mentioning that the authors compared LC3-II levels 
upon lysosomal inhibition between pre- and postsurgical conditions, but it was not specified whether 
autophagic flux was modified in each condition due to lysosomal inhibition. Then, it is not clear 
whether autophagic flux was or was not impaired in each condition. Modulation of sWAT autophagy 
by dietary intervention has also been reported in obese patients. Evidence suggests that this 
modulation depends on the type of dietary fat consumed. Specifically, an enriched monounsaturated 
fatty acid diet led to an increase in sWAT Beclin-1 and ATG7 gene expression [183]. This increase in 
gene expression of autophagic markers was concomitant with a decrease in postprandial oxidative 
stress in sWAT [184], so the protective role of autophagy was again claimed, in this case, against 
nutritional stress. The authors hypothesized that monounsaturated fatty acids elicit a better adaptive 
response than saturated fatty acids or carbohydrates [183]. Unfortunately, changes in the expression 
of autophagic genes were not analyzed regarding diet-induced metabolic changes, with the systemic 
effect of diet-induced autophagic sWAT response remaining unknown.  
6. Concluding Remarks 
Experimental data have revealed the involvement of autophagy in the different processes 
triggered during WAT expansion. Autophagy plays a relevant role in white adipogenesis, likely 
favoring hyperplasic expansion of WAT. In addition, the protective role of autophagy in the control 
of the inflammatory response has also been demonstrated in WAT and adipocytes. There is evidence 
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suggesting that autophagy may be involved in ECM remodeling, though a wider overview and more 
in-depth studies are required to gain insight into the contribution of autophagy in WAT fibrosis. 
Given this general outline, autophagy activation in WAT may be beneficial for tissue homeostasis 
and healthy expansion. However, it should be kept in mind that not all studies could confirm the 
sense in which autophagy participates in each of these processes. Several issues may be influencing 
the discordant findings. Firstly, many of the contradictory results come from animal models of 
genetic autophagy deletion which target disparate autophagy-related genes. Thus, it should be 
considered that different autophagic molecules might have different weight on the global autophagic 
process, and compensatory mechanisms should not be discarded. Furthermore, non-canonical 
functions for autophagic proteins have been also reported [102] and then, the consequences of single 
autophagic gene deletion might also be the result of their autophagy-independent roles. Many 
regulatory pathways other than autophagy control WAT physiology and the participation of 
autophagy should be regarded as a part of the whole WAT regulatory network.  
Once the implication of autophagy in WAT expandability has been established, the next question 
is whether the maladaptive WAT expansion in obesity and/or metabolic disruption is related to WAT 
autophagy alterations. In this regard, human studies have given some clues. Most of the studies point 
to an overactivation of WAT autophagy in obesity. When put into the context of experimental data, 
several assumptions can be raised. Autophagy overactivation may result in hyperplasic WAT 
expansion because of enhanced white adipogenesis. This may be somewhat contradictory if 
considered WAT hyperplasia as the healthy way to expand. Then, autophagy can be regarded as a 
protective mechanism to avoid WAT maladaptation to nutritional stress. This would also explain 
enhanced autophagy despite the increased inflammation in dysfunctional WAT (that it might be even 
worse in the case of decreased autophagy). On the other hand, it should be borne in mind that 
metabolic dysregulation is not always associated with obesity. Current studies have only addressed 
the case of obese patients with altered glycemic status. The few studies that included non-diabetic 
obese patients showed that autophagy overactivation might be not necessarily linked to obesity per 
se. Taking into consideration that autophagy is highly regulated by nutritional sensors, particularly 
by insulin, the insulin-resistant state or diabetes are likely influencing WAT autophagy even more 
than obesity itself. However, this question remains unsolved and the autophagic status should also 
be assessed in non-obese diabetic patients to elucidate the actual relationship between autophagy, 
glycemic dysregulation, and obesity.  
Given the implication of autophagy in WAT and other metabolic tissues, it has been proposed 
as a putative therapeutic target. However, many gaps remain to be filled before targeting autophagy 
to treat metabolic diseases. For instance, the inverse trend in autophagy activation or suppression in 
the different metabolic organs related to obesity or diabetes. This highlights the necessity of tissue-
targeted strategies to manage autophagy. But even in the same tissue, cell heterogeneity also makes 
this approach difficult, as autophagy has different functions depending on cell type. This takes special 
relevance in WAT where fibroblasts, preadipocytes, mature adipocytes, and immune cells coexist. 
Further comprehensive studies should be developed to shed light on the tangled network which links 
autophagy with each regulatory pathway in WAT.  
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